The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for New England Biolabs sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights New England Biolabs Inc, United States Revenue

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

New England Biolabs Inc (NEB) is a life science company that develops recombinant and native enzymes for genomic research. It offers various products such as competent cells, DNA plasmids, protein tools, buffers and strains, and others. The company has applications in cloning and synthetic biology, RNA analysis, DNA amplification and PCR, DNA modification, library preparation for next generation sequencing and epigenetic, among others. NEB also provides interactive tools for research and experimental designs. The company offers a challenging and creative work environment in a state of the art research and production facility. It has its presence with subsidiaries in Canada, China, France, Germany, Japan, Singapore and the UK. The company offers its products globally through a channel of network distributors. NEB is headquartered in Ipswich, Massachusetts, the US. Key subsidiaries of New England Biolabs include New England Biolabs, New England Biolabs France, New England Biolabs Japan, New England Biolabs and New England Biolabs (UK).

The key metrics of New England Biolabs related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As New England Biolabs is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as New England Biolabs.

For a detailed understanding of the performance of New England Biolabs, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.